Sommario

• • ·COVID-19 and the US health insurance conundrum

    Pagina :733

     
• • ·Cancer detection: the quest for a single liquid biopsy for all

    Pagina :733

     
• • ·CDK4/6 inhibition in HER2-positive breast cancer

    Pagina :734-735

    Nicolò Matteo Luca Battisti, Alistair Ring

     
• • ·New mitomycin formulation for low-grade upper tract urothelial cancer

    Pagina :735-736

    Robert Dreicer

     
• • ·Neoadjuvant atezolizumab plus chemotherapy in resectable non-small-cell lung cancer

    Pagina :736-738

    Rafael Rosell, Masaoki Ito

     
• • ·Towards greater clarity in the treatment of cholangiocarcinoma

    Pagina :738-739

    Christelle de la Fouchardiere

     
• • ·Combined immunotherapy and VEGF-antagonist in hepatocellular carcinoma: a step forward

    Pagina :740-741

    Sherrie Bhoori, Vincenzo Mazzaferro

     
• • ·Immune checkpoint inhibitor plus anti-HER2 therapy: a new standard for HER2-positive oesophagogastric cancer?

    Pagina :741-743

    Yukiya Narita, Shigenori Kadowaki, Kei Muro

     
• • ·Is chemotherapy for advanced or metastatic oesophageal squamous cell carcinoma no longer needed?

    Pagina :743-745

    Hanneke WM van Laarhoven

     
• • ·Lenvatinib for thymic carcinomas

    Pagina :745-746

    Nobuyuki Takahashi, Anish Thomas

     
• • ·Minimally invasive surgery and quality of life in cervical cancer

    Pagina :746-748

    Gabriella Ferrandina, Giacomo Corrado, Giovanni Scambia

     
• • ·Impact of the COVID-19 pandemic on the symptomatic diagnosis of cancer: the view from primary care

    Pagina :748-750

    Daniel Jones, Richard D Neal, Sean R G Duffy, Suzanne E Scott, Katriina L Whitaker, Kate Brain

     
• • ·Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands

    Pagina :750-751

    Avinash G Dinmohamed, Otto Visser, Rob H A Verhoeven, Marieke W J Louwman, Francien H van Nederveen, Stefan M Willems, Matthias A W Merkx, Valery E P P Lemmens, Iris D Nagtegaal, Sabine Siesling

      
• • ·Initiation of the Global Coalition for Radiotherapy during the COVID-19 pandemic

    Pagina :752-753

    Pat Price, Shandi E Barney

     
• • ·Early impact of the COVID-19 pandemic on paediatric cancer care in Latin America

    Pagina :753-755

    Liliana Vasquez, Claudia Sampor, Gabriela Villanueva, Essy Maradiegue, Mercedes Garcia-Lombardi, Wendy Gomez-García, Florencia Moreno, Rosdali Diaz, Andrea M Cappellano, Carlos Andres Portilla, Beatriz Salas, Evelinda Nava, Silvia Brizuela, Soledad Jimenez, Ximena Espinoza, Pascale Yola Gassant, Karina Quintero, Soad Fuentes-Alabi, Thelma Velasquez, Ligia Fu, Yessika Gamboa, Juan Quintana, Mariela Castiglioni, Cesar Nuñez, Arturo Moreno, Sandra Luna-Fineman, Silvana Luciani, Guillermo Chantada

      
• • ·NIH funding for research underlying new cancer therapies

    Pagina :755-757

    Ekaterina Galkina Cleary, Fred D Ledley

      
• • ·Effectiveness of anti-PD-1 for hepatocellular carcinoma

    Pagina :e293

    Rui Liao

    
• • ·Effectiveness of anti-PD-1 for hepatocellular carcinoma – Authors’ reply

    Pagina :e294

    Shukui Qin, Zhenggang Ren, Zhiqiang Meng, Zhendong Chen, Xiaoli Chai

    
• • ·Top ten research priorities for pancreatic cancer therapy

    Pagina :e295

    Rosa Klotz, Colette Doerr-Harim, Azaz Ahmed, Christine Tjaden, Maryrose Tarpey, Markus K Diener, Thilo Hackert, André L Mihaljevic, Priority Setting Partnership Pancreatic Cancer

    
• • ·Knowing your tumour?

    Pagina :e297

    Ian F Tannock, John A Hickman

    
• • ·TRIBE2 results and toxicity

    Pagina :e298

    Jianwei Zhang, Yue Cai, Xiaoyu Xie, Huabin Hu, Yanhong Deng

    
• • ·TRIBE2 results and toxicity

    Pagina :e299

    Antonio Avallone, Francesco Giuliani

    
• • ·TRIBE2 results and toxicity – Authors’ reply

    Pagina :e300

    Carlotta Antoniotti, Chiara Cremolini, Daniele Rossini, Alfredo Falcone

    
• • ·Less is more? Imaging-based target volume reduction

    Pagina :e302

    Eivind Blais, Idriss Troussier

    
• • ·Less is more? Imaging-based target volume reduction – Authors’ reply

    Pagina :e303

    Ursula Nestle, Tanja Schimek-Jasch, Jochem König

    
• • ·Correction to Lancet Oncol 2019; 20: 1286–94

    Pagina :e304

    
• • ·Correction to Lancet Oncol 2019; 20: 1370–85

    Pagina :e304

    
• • ·Correction to Lancet Oncol 2020; 21:750–51

    Pagina :e304

    
• • ·COVID-19: consequences for higher education

    Pagina :758

    Talha Khan Burki

     
• • ·Summary of international recommendations in 23 languages for patients with cancer during the COVID-19 pandemic

    Pagina :759-760

    Davide Mauri, Konstantinos Kamposioras, Maria Tolia, Filippo Alongi, Dimitrios Tzachanis, International Oncology Panel and European Cancer Patient Coalition collaborators, Branka Petricevic, Nataliya Chilingirova, Iglika Mihaylova, Theodoros Tsakiridis, Carl Salembier, Konstantinos Papadimitriou, Ramon Andrade De Mello, Giovanna Araujo Amaral, Nathália Moisés Neves, Rodrigo Dias, Junlin Yi, Natalija Dedic Plavetic, Katarina Antunac, Panteleimon Kountourakis, Jindrich Kopecky, Christos Christopoulos, Ida Pavese, Stefanie Corradini, George Zarkavelis, Alexandra Papadaki, Areti Gkantaifi, Vasilios Theodorelos, Antonio Capizzello, Jozsef Lovey, Francesco Cellini, Mario Dambrosio, Dan Takeuchi, Haytham Hamed Saraireh, Ranveig Røtterud, Marzanna Chojnacka, Athanasios Papachristos, Igor Djan, Lazar Popovic, Cvetka Grašic Kuhar, Primož Strojan, Nadia Hindi, Antonis Valachis, Mari Åhs, Berardino De Bari, Olalla Santa Cruz, Hassan Hameed, Elena Takeuchi, Kathi Apostolidis, Antonella Cardone, Paulina Gono, Panagiotis Filis

      
• • ·COVID-19 and cancer care in Bermuda

    Pagina :761-762

    Christopher Fosker

     
• • ·Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial

    Pagina :763-775

    Sara M Tolaney, Andrew M Wardley, Stefania Zambelli, John F Hilton, Tiffany A Troso-Sandoval, Francesco Ricci, Seock-Ah Im, Sung-Bae Kim, Stephen RD Johnston, Arlene Chan, Shom Goel, Kristen Catron, Sonya C Chapman, Gregory L Price, Zhengyu Yang, M Corona Gainford, Fabrice André

    Riassunto Riassunto Mappa Mappa   
• • ·Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial

    Pagina :776-785

    Nir Kleinmann, Surena F Matin, Phillip M Pierorazio, John L Gore, Ahmad Shabsigh, Brian Hu, Karim Chamie, Guilherme Godoy, Scott Hubosky, Marcelino Rivera, Michael O’Donnell, Marcus Quek, Jay D Raman, John J Knoedler, Douglas Scherr, Joshua Stern, Christopher Weight, Alon Weizer, Michael Woods, Hristos Kaimakliotis, Angela B Smith, Jennifer Linehan, Jonathan Coleman, Mitchell R Humphreys, Raymond Pak, David Lifshitz, Michael Verni, Mehrad Adibi, Mahul B Amin, Elyse Seltzer, Ifat Klein, Marina Konorty, Dalit Strauss-Ayali, Gil Hakim, Mark Schoenberg, Seth P Lerner

    Riassunto Riassunto Mappa Mappa   
• • ·Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial

    Pagina :786-795

    Catherine A Shu, Justin F Gainor, Mark M Awad, Codruta Chiuzan, Claud M Grigg, Aliyah Pabani, Robert F Garofano, Mark B Stoopler, Simon K Cheng, Abby White, Michael Lanuti, Frank D’Ovidio, Matthew Bacchetta, Joshua R Sonett, Anjali Saqi, Naiyer A Rizvi

    Riassunto Riassunto Mappa Mappa   
• • ·Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

    Pagina :796-807

    Ghassan K Abou-Alfa, Teresa Macarulla, Milind M Javle, Robin K Kelley, Sam J Lubner, Jorge Adeva, James M Cleary, Daniel V Catenacci, Mitesh J Borad, John Bridgewater, William P Harris, Adrian G Murphy, Do-Youn Oh, Jonathan Whisenant, Maeve A Lowery, Lipika Goyal, Rachna T Shroff, Anthony B El-Khoueiry, Bin Fan, Bin Wu, Christina X Chamberlain, Liewen Jiang, Camelia Gliser, Shuchi S Pandya, Juan W Valle, Andrew X Zhu

    Riassunto Riassunto Mappa Mappa   
• • ·Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study

    Pagina :808-820

    Michael S Lee, Baek-Yeol Ryoo, Chih-Hung Hsu, Kazushi Numata, Stacey Stein, Wendy Verret, Stephen P Hack, Jessica Spahn, Bo Liu, Heba Abdullah, Yulei Wang, Aiwu Ruth He, Kyung-Hun Lee, GO30140 investigators, Y-J Bang, J Bendell, Y Chao, J-S Chen, H C Chung, S L Davis, A Dev, E Gane, B George, A R He, H Hochster, C-H Hsu, M Ikeda, J Lee, M Lee, A Mahipal, G Manji, M Morimoto, K Numata, M Pishvaian, S Qin, D Ryan, B-Y Ryoo, N Sasahira, S Stein, J Strickler, N Tebbutt

    Riassunto Riassunto Mappa Mappa   
• • ·First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial

    Pagina :821-831

    Yelena Y Janjigian, Steven B Maron, Walid K Chatila, Brittanie Millang, Shweta S Chavan, Carly Alterman, Joanne F Chou, Michal F Segal, Marc Z Simmons, Parisa Momtaz, Marina Shcherba, Geoffrey Y Ku, Alice Zervoudakis, Elizabeth S Won, David P Kelsen, David H Ilson, Rebecca J Nagy, Richard B Lanman, Ryan N Ptashkin, Mark T A Donoghue, Marinela Capanu, Barry S Taylor, David B Solit, Nikolaus Schultz, Jaclyn F Hechtman

    Riassunto Riassunto Mappa Mappa   
• • ·Camrelizumab versus investigator’s choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study

    Pagina :832-842

    Jing Huang, Jianming Xu, Yun Chen, Wu Zhuang, Yiping Zhang, Zhendong Chen, Jia Chen, Helong Zhang, Zuoxing Niu, Qingxia Fan, Lizhu Lin, Kangsheng Gu, Ying Liu, Yi Ba, Zhanhui Miao, Xiaodong Jiang, Ming Zeng, Jianhua Chen, Zhichao Fu, Lu Gan, Jun Wang, Xianbao Zhan, Tianshu Liu, Zhiping Li, Lin Shen, Yongqian Shu, Tao Zhang, Qing Yang, Jianjun Zou, ESCORT Study Group, Suxia Luo, Feng Peng, Gang Wu, Nong Xu, Lin Zhao, Dong Ma, Shukui Qin, Wei Ren, Enxiao Li, Hongda Lu, Yueyin Pan, Jianping Xiong, Ying Yuan, Yuxian Bai, Lei Chen, Yi Hu, Li Zhang, Yong Gao

    Riassunto Riassunto Mappa Mappa   
• • ·Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial

    Pagina :843-850

    Jun Sato, Miyako Satouchi, Shoichi Itoh, Yusuke Okuma, Seiji Niho, Hidenori Mizugaki, Haruyasu Murakami, Yasuhito Fujisaka, Toshiyuki Kozuki, Kenichi Nakamura, Yukari Nagasaka, Mamiko Kawasaki, Tomoaki Yamada, Ryunosuke Machida, Aya Kuchiba, Yuichiro Ohe, Noboru Yamamoto

    Riassunto Riassunto Mappa Mappa   
• • ·Quality of life in patients with cervical cancer after open versus minimally invasive radical hysterectomy (LACC): a secondary outcome of a multicentre, randomised, open-label, phase 3, non-inferiority trial

    Pagina :851-860

    Michael Frumovitz, Andreas Obermair, Robert L Coleman, Rene Pareja, Aldo Lopez, Reitan Ribero, David Isla, Gabriel Rendon, Marcus Q Bernardini, Alessandro Buda, Renato Moretti-Marquez, Albert Zevallos, Marcelo A Vieira, Tao Zhu, Russell P Land, James Nicklin, Rebecca Asher, Kristy P Robledo, Val Gebski, Pedro T Ramirez

    Riassunto Riassunto Mappa Mappa   
• • ·Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group

    Pagina :e305

    Jason Fangusaro, Olaf Witt, Pablo Hernáiz Driever, Asim K Bag, Peter de Blank, Nadja Kadom, Lindsay Kilburn, Robert M Lober, Nathan J Robison, Michael J Fisher, Roger J Packer, Tina Young Poussaint, Ludmila Papusha, Shivaram Avula, Alba A Brandes, Eric Bouffet, Daniel Bowers, Anton Artemov, Murali Chintagumpala, David Zurakowski, Martin van den Bent, Brigitte Bison, Kristen W Yeom, Walter Taal, Katherine E Warren

    Riassunto Riassunto Mappa Mappa   
• • ·Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group

    Pagina :e317

    Craig Erker, Benita Tamrazi, Tina Y Poussaint, Sabine Mueller, Daddy Mata-Mbemba, Enrico Franceschi, Alba A Brandes, Arvind Rao, Kellie B Haworth, Patrick Y Wen, Stewart Goldman, Gilbert Vezina, Tobey J MacDonald, Ira J Dunkel, Paul S Morgan, Tim Jaspan, Michael D Prados, Katherine E Warren

    Riassunto Riassunto Mappa Mappa  
• • ·Response assessment in diffuse intrinsic pontine glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group

    Pagina :e330

    Tabitha M Cooney, Kenneth J Cohen, Carolina V Guimaraes, Girish Dhall, James Leach, Maura Massimino, Alessandra Erbetta, Luisa Chiapparini, Fatema Malbari, Kim Kramer, Ian F Pollack, Patricia Baxter, Suzanne Laughlin, Zoltán Patay, Tina Young Poussaint, Katherine E Warren

    Riassunto Riassunto Mappa Mappa  
• • ·Sister Mary Joseph nodule in mantle cell lymphoma

    Pagina :e337

    Niamh O’Connor-Byrne, Siobhan Glavey, Declan de Freitas, John Quinn